CN112041340A - 用于治疗肿瘤和/或转移的抗ghfr抗体和hegfr的组合 - Google Patents

用于治疗肿瘤和/或转移的抗ghfr抗体和hegfr的组合 Download PDF

Info

Publication number
CN112041340A
CN112041340A CN201980020753.XA CN201980020753A CN112041340A CN 112041340 A CN112041340 A CN 112041340A CN 201980020753 A CN201980020753 A CN 201980020753A CN 112041340 A CN112041340 A CN 112041340A
Authority
CN
China
Prior art keywords
hgfr
human
antibody fragment
extracellular portion
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980020753.XA
Other languages
English (en)
Chinese (zh)
Inventor
C·巴西利克
E·维格纳
P·M·科蒙利奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Medex Precision Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medex Precision Pharmaceutical Co ltd filed Critical Medex Precision Pharmaceutical Co ltd
Publication of CN112041340A publication Critical patent/CN112041340A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980020753.XA 2018-03-22 2019-03-21 用于治疗肿瘤和/或转移的抗ghfr抗体和hegfr的组合 Pending CN112041340A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102018000003875A IT201800003875A1 (it) 2018-03-22 2018-03-22 Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi
IT102018000003875 2018-03-22
PCT/IB2019/052307 WO2019180658A1 (en) 2018-03-22 2019-03-21 Combination of anti-hgfr antibody and hegfr for the treatment of a tumor and/or metastasis

Publications (1)

Publication Number Publication Date
CN112041340A true CN112041340A (zh) 2020-12-04

Family

ID=62530500

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980020753.XA Pending CN112041340A (zh) 2018-03-22 2019-03-21 用于治疗肿瘤和/或转移的抗ghfr抗体和hegfr的组合

Country Status (13)

Country Link
US (1) US11814433B2 (OSRAM)
EP (1) EP3768710A1 (OSRAM)
JP (1) JP7381555B2 (OSRAM)
KR (1) KR20200135449A (OSRAM)
CN (1) CN112041340A (OSRAM)
AU (1) AU2019240274B2 (OSRAM)
BR (1) BR112020018981A8 (OSRAM)
CA (1) CA3093513A1 (OSRAM)
IL (1) IL277476B2 (OSRAM)
IT (1) IT201800003875A1 (OSRAM)
MX (1) MX2020009787A (OSRAM)
SG (1) SG11202008612XA (OSRAM)
WO (1) WO2019180658A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3413363B1 (en) * 2016-02-02 2021-03-24 National Institute for Materials Science Ferromagnetic tunnel junction, magnetoresistive effect element and spintronics device in which said ferromagnetic tunnel junction is used, and method of manufacturing ferromagnetic tunnel junction
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025188676A1 (en) * 2024-03-04 2025-09-12 The Board Of Trustees Of The Leland Stanford Junior University Genetic engineering of cells for secretion of therapeutic antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080300273A1 (en) * 2005-12-05 2008-12-04 Pfizer Inc. Method of Treating Abnormal Cell Growth
CN101379192A (zh) * 2006-02-06 2009-03-04 梅思尔斯平移研究有限公司 治疗肿瘤的抗Met单克隆抗体及其片段和载体及相应产品
CN101914161A (zh) * 2010-08-13 2010-12-15 四川大学 抑制肿瘤生长的融合蛋白HGFα-Fc及其用途
CN104968684A (zh) * 2013-01-09 2015-10-07 梅思尔斯平移研究有限公司 新的抗体片段、组合物和其用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080300273A1 (en) * 2005-12-05 2008-12-04 Pfizer Inc. Method of Treating Abnormal Cell Growth
CN101379192A (zh) * 2006-02-06 2009-03-04 梅思尔斯平移研究有限公司 治疗肿瘤的抗Met单克隆抗体及其片段和载体及相应产品
CN101914161A (zh) * 2010-08-13 2010-12-15 四川大学 抑制肿瘤生长的融合蛋白HGFα-Fc及其用途
CN104968684A (zh) * 2013-01-09 2015-10-07 梅思尔斯平移研究有限公司 新的抗体片段、组合物和其用途
US20160017044A1 (en) * 2013-01-09 2016-01-21 Metheresis Translational Research S.A. New antibody fragments, compositions and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MODICA等: "Vertical inhibition of Met by dual decoy anti body strategy", 2ND EACR-OECI CONFERENCE, 16 March 2017 (2017-03-16), pages 36 *
PETRELLI等: "Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity", PNAS, vol. 103, no. 13, 28 March 2006 (2006-03-28), pages 5090, XP002389316, DOI: 10.1073/pnas.0508156103 *
缪鑫;刘政;: "消化道肿瘤中的肝细胞生长因子受体信号靶向治疗研究进展", 胃肠病学和肝病学杂志, no. 04, 20 April 2017 (2017-04-20), pages 365 - 368 *

Also Published As

Publication number Publication date
BR112020018981A2 (pt) 2021-01-05
US20210070868A1 (en) 2021-03-11
JP7381555B2 (ja) 2023-11-15
WO2019180658A1 (en) 2019-09-26
IL277476A (en) 2020-11-30
US11814433B2 (en) 2023-11-14
MX2020009787A (es) 2020-11-09
CA3093513A1 (en) 2019-09-26
AU2019240274B2 (en) 2025-04-24
IL277476B1 (en) 2026-01-01
JP2021518170A (ja) 2021-08-02
RU2020129465A (ru) 2022-04-22
AU2019240274A1 (en) 2020-10-15
BR112020018981A8 (pt) 2022-06-28
KR20200135449A (ko) 2020-12-02
IL277476B2 (en) 2026-05-01
IT201800003875A1 (it) 2019-09-22
EP3768710A1 (en) 2021-01-27
SG11202008612XA (en) 2020-10-29

Similar Documents

Publication Publication Date Title
AU2014249405B2 (en) Fusion immunomodulatory proteins and methods for making same
BRPI0707480A2 (pt) usos de um anticorpo monoclonal, um fragmento e/ou anticorpo geneticamente engenheirado ou humanizado, de uma seqüência de nucleotìdeos e de um vetor, produto, e, método para triar compostos
KR20230010221A (ko) 암 치료를 위한 암 요법과 병용된 다량체 항-dr5 결합 분자의 용도
US20250101115A1 (en) Anti-met fab-fc for the treatment of a tumor and/or metastasis
US11814433B2 (en) Combination of anti-HGFR antibody and HEGFR for the treatment of a tumor and/or metastasis
Basilico et al. Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody‐“decoy” strategy
Vigna et al. Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30
TR201808826T4 (tr) Yeni antikor fragmentleri, bileşimleri ve bunların kullanımları.
EP3440111B1 (en) Anti-vegfr-1 antibodies and uses thereof
US20120121589A1 (en) Modified egfr ectodomain
HK40119612A (zh) 用於治疗肿瘤和/或转移的抗met fab-fc
RU2788606C2 (ru) Комбинация антитела против hgfr и hegfr для лечения опухоли и/или метастаза
Benvenuti et al. Discovery and Function of the HGF/MET and the MSP/RON Kinase Signaling Pathways in Cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20220214

Address after: Basel, Switzerland

Applicant after: Vertical biology Co.,Ltd.

Address before: Torino

Applicant before: Medex precision Pharmaceutical Co.,Ltd.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20241205

Address after: Laval, France

Applicant after: PIERRE FABRE MEDICAMENT

Country or region after: France

Address before: Basel, SUI

Applicant before: Vertical biology Co.,Ltd.

Country or region before: Switzerland

TA01 Transfer of patent application right